

Tissue Source Site (TSS) Name: _____ Completed By: ______ _____ HCMI Identifier (ID3): _ Completion Date (MM/DD/YYYY): _

Form Notes: An Enrollment Form should be completed for each HCMI case upon qualification notice from Leidos. All information provided on this form should include activity from the Date of Initial Pathologic Diagnosis to the most recent Date of Last Contact with the patient.

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
1	ID2		2003301	Provide the patient's ID2 (this ID will only be used by IMS for internal quality control).
2	ID3		5845012	Provide the HCMI-specific anonymized ID (ID3).
3	Index date	 Initial pathologic diagnosis Sample procurement First patient visit 	6154722	Select the reference date used to calculate time intervals (e.g. days to treatment). Date of initial pathologic diagnosis is the HCMI standard and should be used unless it is unavailable. If an alternative index date is used, indicate it here and use it for all interval calculations.
Patient Info	ormation		-	
4	Number of days from index date to date of last contact		3008273	Provide the number of days from the index date to the date of last contact.
5	Patient age on index date		6379572	Provide the age (in days) of the patient on the index date. <i>Note: If the patient's age is greater than</i> 32,872 days (90 years), please enter 32,872.
6	Gender	□ Male□ Female□ Unspecified	2200604	Provide the patient's gender using the defined categories. Identification of gender is based upon self-report and may come from a form, questionnaire, interview, etc.
7	Height		649	Provide the patient's height, in centimeters.
8	Weight		651	Provide the patient's weight, in kilograms.
9	Body mass index (BMI)		2006410	If the patient's height and weight are not collected, provide the patient's body mass index (BMI).
10	Race	 American Indian or Alaska Native Asian Black or African American Native Hawaiian or other Pacific Islander White Unknown Not reported 	2192199	 Provide the patient's race using the defined categories. American Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian: A person having origins in any of the peoples of the Far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. Black or African American: A person having origins in any of the black racial groups of Africa. Native Hawaiian or other Pacific Islander: A person having origins on any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Island. White: A person having origins in any of the original peoples of Europe, the Middle East, or North Africa.
11	Ethnicity	 Hispanic or Latino Not Hispanic or Latino Unknown Not reported 	2192217	Provide the patient's ethnicity using the defined categories. Hispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. Not Hispanic or Latino: A person not meeting the definition of Hispanic or Latino.





Tissue Source Site (TSS) Name: ______

	Question Text	Data Entry Options	CDE ID	Instruction Text
12	Year of birth		2896954	Provide the year of the patient's birth. If the
				patient was born prior to 1928, insert the date
				1928.
13	Family history of	Same	5832923	Has a first-degree relative of the patient been
	cancer	Different		diagnosed with a cancer of the same or a
		None		different type?
		Unknown		
14	Smoking history	□ Lifelong non-smoker (<100 cigarettes	2181650	Indicate the patient's history of tobacco smoking
		smoked in a lifetime)		as well as their current smoking status using the
		Current smoker (includes daily and non-		defined categories.
		daily smokers)		
		Current reformed smoker (duration not		
		specified)		
		Current reformed smoker for >15 years		
		□ Current reformed smoker for ≤15 years		
15	Metastasis at		3438571	Indicate whether there was evidence of
	diagnosis	Metastatic		metastasis at the time of diagnosis of the primary
	assessment status	Non-metastatic (confirmed)		tumor. Note: If metastatic at diagnosis, proceed to
		Non-metastatic (unconfirmed)		Question 16, otherwise, skip to Question 17.
16	Metastatic site(s)	Bone	4616511	Indicate the site(s) of metastasis at the time of
10	at diagnosis	□ Bone marrow	4010511	diagnosis of the primary tumor. <i>Note: If the</i>
	at uldgriusis			anatomic site of tumor tissue is not listed, proceed to
		 Lymph nodes (regional) Lymph nodes (distant) 		Question 16a, otherwise, skip to Question 17.
		 Other (specify) 		
16a	Specify metastatic		3128033	If the site(s) of metastasis at the time of diagnosis
100	site		5120055	of the primary tumor is not included in the
	Site			provided list, specify the site(s).
iospecime	n Information			
17	Tissue sample	Normal tissue	2006911	Please select all the tissue sample types
	type(s) collected	Primary tumor		submitted for HCMI with this case.
	for HCMI for this	□ Metastatic		
	case	Recurrent		
		Other tissue		
10	Number of		6584256	Please provide the number of normal tissue
18	Number of			rieuse provide the number of normal tissue
10	NORMAL tissues			specimens obtained for HCMI for this case. <i>Note:</i>
10				
10	NORMAL tissues			specimens obtained for HCMI for this case. Note:
10	NORMAL tissues biospecimens			specimens obtained for HCMI for this case. Note:
18	NORMAL tissues biospecimens collected for HCMI for this case Number of		6584257	specimens obtained for HCMI for this case. <i>Note:</i> <i>This number is expected to be 1.</i> Please provide the number of primary tumor
	NORMAL tissues biospecimens collected for HCMI for this case		6584257	specimens obtained for HCMI for this case. <i>Note:</i> <i>This number is expected to be 1.</i> Please provide the number of primary tumor specimens obtained for HCMI for this case. <i>Note:</i> A
	NORMAL tissues biospecimens collected for HCMI for this case Number of		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is
	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation
	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is
	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation
	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1.
	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of		6584257	specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue biospecimens			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue biospecimens collected for			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue biospecimens			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue biospecimens collected for			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor
19	NORMAL tissues biospecimens collected for HCMI for this case Number of PRIMARY cancer tissue biospecimens collected for HCMI model development for this case Number of METASTATIC/ RECURRENT cancer tissue biospecimens collected for HCMI model			specimens obtained for HCMI for this case. Note: This number is expected to be 1. Please provide the number of primary tumor specimens obtained for HCMI for this case. Note: A single primary tumor biospecimen obtained that is portioned for both sequencing and model generation counts as 1 single primary tumor specimen. This number is expected to be 1. Please provide the number of metastatic and/or recurrent cancer biospecimens collected for HCMI for this case. Note: A biospecimen obtained from a single site at a single timepoint in progression that is portioned for both sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and





Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
21	Number of OTHER		6584259	Please provide the number of pre-malignant,
	tissue			non-malignant, or dysplastic tissue biospecimens
	biospecimens			collected for HCMI for this case. Note: A
	collected for			biospecimen obtained from a single site at a single
	HCMI model			timepoint in progression that is portioned for both
	development for			sequencing and model generation counts as 1 single
	this case			tumor specimen. A biospecimen obtained from another
				site or at a later timepoint in progression that is portioned
				for both sequencing and model generation counts as a second single tumor specimen.
22	Total number of		6584271	Please provide the total number of tissue
	tissue			biospecimens collected for HCMI for this case.
	biospecimens			Note: This number should be the sum of the normal,
	collected for			primary tumor, metastatic/ recurrent tumor, and other
	HCMI for this case			biospecimen counts above.
lormal Con	trol Information			
23	Normal tissue		6584264	Please provide a number to identify
	biospecimen			which biospecimen this is in the sequence. <i>Note:</i>
	ordinal			This number is expected to be "1".
24	CMDC sample ID		6586035	Please provide the CMDC sample ID for this
				biospecimen as it will appear on tubes and the
				Sample Submission Form transmitted to the BPC
25	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
	(if available)			sample as it will appear on the Sample
				Submission Form transmitted to the BPC.
26	Type of normal	□ Whole blood	3081936	Indicate the type of normal control submitted fo
20	control	□ Buccal cells	0001000	this case.
	control			
		Lymphocytes		
		Extracted DNA from blood		
		Extracted DNA from saliva		
		Extracted DNA from buccal cells		
		Extracted DNA from normal tissue		
		FFPE non-neoplastic tissue		
		Non-neoplastic tissue		
27	Anatomic site of		4132152	If non-neoplastic tissue was submitted as the
	normal tissue	□ Abdomen		normal control, select the anatomic site of the
	normal dissue			
		Adrenal gland		normal tissue. <i>Note: If the anatomic site of normal</i>
		□ Kidney		tissue is not listed, proceed to Question 27a,
		□ Other (specify)		otherwise, skip to Question 28.
27-	Othersentenis	Not applicable	2200400	
27a	Other anatomic		3288189	If non-neoplastic tissue, adjacent tissue, or
	site of normal			normal tissue from another anatomic site was
	tissue			submitted as the normal control, provide the
				anatomic site of the normal tissue.
28	Distance from	$\Box \text{ Adjacent (< or = 2cm)}$	3088708	Indicate the distance from the site of normal
	tumor to normal	Distal (>2cm)		tumor collection to the primary tumor. Note: If
	control tissue (if	🗖 Unknown		normal tissue was not submitted, select 'Not
	not blood)	Not applicable		applicable'.
29	Normal tissue	Cryopreserved	5432521	Provide the method used to preserve the norma
	sample	□ FFPE		tissue sample collected for molecular
	preservation	□ Frozen		characterization.
	method			
		□ Snap frozen		
Primary Tw	nor Biospecimen Info			
30	ICD-10 code for		3226287	Provide the ICD-10 code for the primary tumor a
	primary tumor	□ 30.0 □ 74.9		used to generate the ID3 for this subject. <i>Note: If</i>
		□ 72.2 □ Other (specify)		the ICD-10 code is not listed, proceed to 30a,



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
30a	Other ICD-10 code for primary tumor		3226287	If the ICD-10 code for the tumor used to generate the model submitted to HCMI is not included on the provided list, specify the ICD-10 code.
31	Tumor morphology	 9490/3 (Ganglioneuroblastoma) 9500/3 (Neuroblastoma, NOS) 9504/3 (Spongioneuroblastoma) 9522/3 (Olfactory neuroblastoma) Other (specify) 	3226275	Using the patient's pathology/laboratory report, provide the ICD-O-3 histology code of the primary tumor. Note: If the ICD-O-3 histology code of the primary tumor is not listed, proceed to Question 31a, otherwise, skip to Question 32.
31a	Other morphology		3226275	If the ICD-O-3 histology code describing the morphology of the patient's primary tumor is not included on the previous list, provide the ICD-O-3 histology code.
32	Tissue or organ of origin	 Adrenal gland Extra-adrenal Other (specify) 	3427536	Using the patient's pathology/laboratory report, select the primary site of the disease. Note: If the tissue or organ of origin is not listed, proceed to Question 32a, otherwise, skip to Question 33.
32a	Other tissue or organ of origin	□Abdomen□Other ill-def□Accessory sinus□Palate□Adrenal gland□Pancreas□Anus□Penis□Appendix□Peripheral□Badder□nerves and□Bone□nerves and□Bone□nerves and□Breast□Peritoneum□subcutaneous□Peritoneum□and other soft□Pharynx□Esophagus□Prostate gla□Gallbladder□gunction□Gallbladder□Renal pelvis□Gallbladder□Skin□Lip□Spleen□Liver□Spleen□Liver□Stomach□Lung□Tonsil□Male genital□Thyroid glarorgans□Tongue□□Mouth□Unknown□Nasopharynx□Urinary syst□Oropharynx□Uterus□Vagina□Vulva	tem nd nd d neu ne ud em	If the primary site of the disease is not included on the previous list, select the primary site of the disease.
33	Histological type		3294805	Provide the traditional surgical pathology text
34	Histology	 Favorable Unfavorable Unknown 	4616372	description of the histological tumor type. Using the patient's pathology/laboratory report, select the histology of the tumor submitted to the HCMI.



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
35	Prior malignancy (of the same cancer type)	Yes No Unknown	5832924	Indicate whether the patient has a history of prior malignancy of the same cancer type.
36	Prior malignancy (other cancer type)	Ves No Unknown	5878828	Indicate whether the patient has a history of prior malignancy of a different cancer type.
37	International Neuroblastoma Risk Group classification system stage	□ L1 □ L2 □ M □ MS	5777238	Indicate the patient's INRG stage.
38	INSS stage	 Stage 1 Stage 2A Stage 2B Stage 3 Stage 4 Stage 4S Unknown 	2974055	Indicate the patient's International Neuroblastoma Staging System disease stage.
39	COG risk classification	 Low risk Intermediate risk High risk Unknown 	4616452	Indicate the patient's risk classification according to the Children's Oncology Group (COG).
40	INPC grade of neuroblastic differentiation	 Undifferentiated Poorly differentiated Differentiating Unknown 	4616392	Indicate the grade of neuroblastic differentiation according to the revised International Neuroblastoma Pathology Classification (INPC).
41	Is necrosis present?	Yes No Unknown	64740	Indicate whether necrosis was present in the primary tumor.
42	MYCN gene amplification status	 Amplified Not amplified Not done Unknown 	4616052	Indicate the amplification status of the MYCN gene.
43	DNA ploidy analysis by flow cytometry	 Diploid (DI=1) Hyperdiploid (DI>1) Unknown 	4616354	Select the DNA ploidy analysis by flow cytometry test result. Note: If DNA ploidy was hyperdiploid, proceed to Question 44, otherwise, skip to Question 45.
44	DNA ploidy analysis by flow cytometry result value		4824055	Specify the numerical result of the DNA ploidy analysis by flow cytometry.
45	INPC mitosis karyorrhexis index	 Low Intermediate High Unknown 	4616412	Indicate the mitosis karyorrhexis index category according to the revised International Neuroblastoma Pathology Classification (INPC).
46	Was ALK mutation analysis performed?	Yes No Unknown	3773874	Indicate whether ALK mutation status was assessed. Note: If ALK mutation analysis was not performed, skip to Question 49.
47	Was a mutation in ALK identified?	□ Yes □ No	3774202	Indicate whether a mutation in ALK was identified. Note: If an ALK mutation was not identified, skip to Question 49.
48	If ALK mutation identified, which one?	 □ F1174C □ F1174L □ F1174V □ F1245L □ K1062M □ R1275Q □ T1087I □ Other (specify) 	6060279	If ALK mutation identified, which one? <i>Note: If the ALK mutation is not listed, proceed to Question 48a, otherwise, skip to Question 49.</i>



Tissue Source Site (TSS) Name: ______


Enrollment: Neuroblastoma

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
48a	Other ALK		6101680	If the ALK mutation identified is not included in
	mutation			the provided list, specify the ALK mutation
				identified.
Primary Tu	mor Sample Informati	ion	•	1
49	Are you			If yes, proceed to question 50.
	submitting a	□ Yes		If submitting a metastatic/recurrent tumor
	primary tumor			biospecimen, proceed to Question 75.
	tissue sample for			
	this case?			
50	Primary tumor		6584265	Please provide a number to identify which
	biospecimen			biospecimen this is in the sequence. Note: The firs
	ordinal			biospecimen should be number "1," the second should
F1	CMDC comple ID		6596025	be number "2," etc.
51	CMDC sample ID		6586035	Please provide the CMDC sample ID for this
				biospecimen as it will appear on tubes and the
			6504040	Sample Submission Form transmitted to the BPC.
52	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
	(if available)			sample as it will appear on the Sample
52	Comple very second		6504720	Submission Form transmitted to the BPC.
53	Sample represents	□ Yes	6584730	Does this primary tumor specimen represent the PRIMARY DIAGNOSIS for this Case ID3? Note: If no
	primary diagnosis?			continue to Question 54, otherwise, skip to Question
	ulagnosis?			55.
54	Specify the ICD-10		3226287	Provide the ICD-10 code for the primary tumor
	code			used to generate the model submitted to HCMI.
55	Tumor tissue	Cryopreserved	5432521	Provide the method used to preserve the tumor
	sample	□ FFPE		tissue sample collected for molecular
	preservation	□ Frozen		characterization.
	method	🗆 ост		
		Snap frozen		
56	Anatomic site	□ Abdominal/non-adrenal	5807222	Indicate the anatomic site of the tumor tissue
	from which the	□ Adrenal		used to generate the model for the HCMI.
	tumor was	□ Ascites		Note: If the anatomic site of the primary tumor tissue
	obtained	Bone		is not listed, proceed to Question 56a, otherwise, skip
		Bone marrow		to Question 57.
		Extra-adrenal		
		Lung		
		Lymph node		
		□ Neck		
		Posterior mediastinum		
		Other (specify)		
56a	Other anatomic		5946219	Provide the anatomic site of the tumor tissue
	site from which			sample used to generate the model for HCMI.
	the tumor was			
	obtained			
57	Method of cancer	Core needle biopsy	3103514	Indicate the procedure performed to obtain the
	sample	Excisional biopsy		tumor tissue used to generate the model for
	procurement	Fine needle aspiration		HCMI. Note: If the method of sample procurement is
		Incisional biopsy		not listed, proceed to Question 57a, otherwise, skip to
		Tumor resection		Question 58.
		Other (specify)		
57a	Other method of		2006730	If the procedure performed to obtain the tumor
	sample			tissue is not included in the provided list, specify
	procurement			the procedure.
58	Number of days		3288495	Provide the number of days from the index date
	from index date to			to the date of the procedure that produced the
	date of cancer			tumor tissue submitted for HCMI.
	sample			
	procurement			



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
59	Tumor tissue type	Primary	3288124	Provide the primary tumor tissue type for this
		Additional primary		sample.
Primary Tu	mor Model Informatio	on		
60	Primary model		6594596	Please provide a number to identify
	biospecimen			which biospecimen this is in the sequence. <i>Note:</i>
	ordinal			This number is expected to be "1".
61	CMDC model ID		6586036	Please provide the CMDC model ID
				for this sample as it will appear on tubes and the
				Sample Submission Form transmitted to the BPC.
62	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
	(if available)			sample as it will appear on the Sample
				Submission Form transmitted to the BPC.
63	Model represents	□ Yes	6584730	Does this MODEL represent the PRIMARY
	primary			DIAGNOSIS for this Case ID3?
	diagnosis?			
64	Model's primary		6586035	Enter the CMDC Sample ID of the PRIMARY
	tumor tissue			TUMOR TISSUE from which this model is derived.
	CMDC sample ID			
65	Model's primary		6584265	Enter the biospecimen ordinal of the PRIMARY
	tumor			TUMOR TISSUE from which this model is derived.
	biospecimen			
	ordinal			
Treatment	Information			
66	History of	🗆 No	3382737	Indicate whether the patient received
	neoadjuvant	Yes; radiation prior to resection		neoadjuvant radiation or pharmaceutical
	treatment	Yes; pharmaceutical treatment prior to		treatment. Note: Pharmaceutical therapy is
		resection		addressed in Questions 67-73. Radiation therapy is
		Yes; both radiation and pharmaceutical		addressed in Questions 74-75.
		treatment prior to resection		
		🗖 Unknown		
67	Neoadjuvant	Cytotoxic chemotherapy	5832928	Select all neoadjuvant chemotherapy types that
	chemotherapy	Hormonal		were administered to the patient. Note: Cytotoxic
	type	Immunotherapy (cellular and immune		chemotherapy is addressed in Questions 68-69.
		checkpoint)		Immunotherapy is addressed in Questions 70-71.
		Targeted therapy (small molecule		Targeted therapy is addressed in Questions 72-73.
		inhibitors and targeted antibodies)		
		Not applicable		
68	Neoadjuvant	Busulfan and Melphalan	2853313	Select all chemotherapeutics used for
	chemotherapeutic	Carboplatin		neoadjuvant therapy.
	regimen	Cis-retinoic acid		Note: If neoadjuvant chemotherapy was not given,
		□ Cisplatin		skip to Question 70. If the neoadjuvant
		Cyclophosphamide		chemotherapeutic regimen is not listed, proceed to
		Doxorubicin		Question 68a, otherwise, skip to Question 69.
		Etoposide		
		□ Ifosfamide		
		Topotecan		
		□ Vincristine		
		Vincristine, actinomycin-D,		
		cyclophosphamide (VAC)		
		□ Vincristine, doxorubicin,		
		cyclophosphamide, ifosfamide, etoposide		
		, , , , , , , , , , , , , , , , , , , ,	1	
		(VDC/IE)		
		□ Vincristine, actinomycin-D,		



HCMI Identifier (ID3):

Completion Date (MM/DD/YYYY): _



Tissue Source Site (TSS) Name:	HCMI Id
Completed By:	Completion Date (N
	Vincristine, irinotecan, temozolomide (VIT)

□ High-dose methotrexate, doxorubicin, cisplatin (MAP) □ Other (specify) □ Chemotherapy not given 68a Other 62694 If the neoadjuvant therapy is not included in the neoadjuvant provided list, specify neoadjuvant therapy. chemotherapeutic regimen 69 5102411 Provide the number of days from index date to Days to the date of treatment with neoadjuvant neoadjuvant chemotherapy chemotherapy. treatment from index date 70 6010528 Immunotherapy Select the immunotherapy administered to the Dinutuximab patient. Note: If the immunotherapy is not listed, Other (specify) proceed to Question 70a, otherwise, skip to Question 71. 70a Other 2953828 Provide the name of the immunotherapy immunotherapy administered to the patient. 71 5102411 Provide the number of days from the index date Days to to the date of treatment with immunotherapy. immunotherapy treatment from index date 72 Targeted therapy 6010389 Select the targeted therapy administered to the □ ALK inhibitor patient. Note: If targeted therapy was not □ MIBG administered, skip to Question 74. If the targeted □ Other (specify) therapy is not listed, proceed to Question 72a, otherwise, skip to Question 73. 72a Other targeted 4308476 If the targeted therapy is not included in the therapy provided list, specify targeted therapy. 73 5102411 Provide the number of days from the index date Days to targeted to the date of treatment with targeted therapy. therapy treatment from index date 74 Radiation therapy □ 2D conventional 3028890 Provide the type of radiation therapy that was administered type □ 3D conformal administered to the patient. Note: If radiation therapy was not administered, skip to Question 76. If □ Brachytherapy HDR the radiation therapy is not listed, proceed to Question □ Brachytherapy LDR 74a, otherwise, skip to Question 75. □ IMRT □ Proton Beam □ Stereotactic Body RT □ Stereotactic Radiosurgery □ WBRT □ Other (specify) Unspecified □ Not applicable 74a Other radiation 2195477 If the radiation therapy type is not included in the provided list, specify the type. therapy 75 Days to radiation 5102411 Provide the number of days from the index date treatment from to the date of treatment with radiation therapy. index date Metastatic/Recurrent Tumor Biospecimen Information 76 Are you Indicate whether a metastatic/recurrent tumor submitting a biospecimen was collected for this ID3 case. Note: □ Yes metastatic/ If yes, proceed to Question 77. If submitting an OTHER

□ No

recurrent tumor tissue sample?

tissue sample, proceed to Question 143.



Tissue Source Site (TSS) Name: _____ Completed By: _____ Enrollment: Neuroblastoma

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
77	Metastatic/		6584266	Please provide a number to identify which
	recurrent tissue			biospecimen this is in the sequence. Note: The first
	biospecimen			biospecimen should be number "1", the second should
	ordinal			be number "2", etc.
78	CMDC tissue ID		6586035	Please provide the CMDC sample ID for this
_				biospecimen as it will appear on tubes and the
				Sample Submission Form transmitted to the BPC.
				Sample Submission Form transmitted to the bre.
79	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
75	(if available)		0504515	sample as it will appear on the Sample
				Submission Form transmitted to the BPC.
00	N/atastatia/		F 422F24	
80	Metastatic/	Cryopreserved	5432521	Provide the method used to preserve the
	recurrent tumor	□ FFPE		metastatic/recurrent tumor tissue sample
	tissue sample	🗖 Frozen		collected for molecular characterization.
	preservation	🗖 ОСТ		
	method	Snap frozen		
81	Number of days		6132218	Provide the number of days from the index date
	from index date to			to the date of diagnosis of metastatic/recurrent
	date of diagnosis			disease.
	of metastasis/			
	recurrence			
82	Method of		6587389	Indicate the procedure performed to obtain the
02		Core needle biopsy	0307309	
	metastatic/	Excisional biopsy		metastatic/recurrent tumor tissue. <i>Note: If the</i>
	recurrent cancer	Fine needle aspiration		method of procurement is not listed, proceed to
	sample	Incisional biopsy		Question 82a, otherwise, skip to Question 83.
	procurement	Tumor resection		
		Other method, specify		
82a	Other method of		6587390	If the procedure performed to obtain the tumor
	cancer sample			tissue is not included in the provided list, specify
	procurement			the procedure.
83	Number of days		3288495	Provide the number of days from the index date
00	from index date to		5200+55	to the date of the procedure that produced the
	date of			metastatic/recurrent tumor tissue submitted for
				HCMI.
	metastatic/			
	recurrent sample			
	procurement		6503004	
84	Metastatic/	□ Abdominal/non-adrenal	6587394	Select the site from which the
	recurrent site	Adrenal		metastatic/recurrent tissue used to develop the
		□ Ascites		model was derived. Note: If the
		🗖 Bone		metastatic/recurrent site is not listed, proceed to
		Bone marrow		Question 84a, otherwise, skip to Question 85.
		Extra-adrenal		
		🗖 Lung		
		Lymph node(s) regional		
		Lymph node(s) distant		
		□ Neck		
		Posterior mediastinum		
		 Other (specify) 		
84a	Other metastatic/		6587395	If not included in the previous list, specify the site
0 4 a	recurrent site		0307393	from which the metastatic/recurrent tissue used
	i courrent site			
0	Site of release		2002505	to develop the model was derived.
85	Site of relapse		2002506	If the primary tumor relapsed, provide the site of
		Regional		relapse.
		Distant		
		Not applicable		
86	ICD-10 code		3226287	Provide the ICD-10 code for the
				metastatic/recurrent tumor used to generate the
			1	model submitted to HCMI.



Tissue Source Site (TSS) Name: ______ Completed By: _____ Enrollment: Neuroblastoma

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
87	ICD-O-3 histology		3226275	Provide the ICD-O-3 histology code describing the
	code			morphology of the metastatic/recurrent tumor
				used to generate the model submitted to HCMI.
88	Maintenance		6119066	Provide the name(s) of the maintenance and/or
	and/or			consolidation therapy administered to the patient
	consolidation			prior to the collection of the metastatic/recurrent
	therapy			tissue used to develop the model.
	administered			
	prior to collection			
	of metastatic/			
	recurrent tissue			
89	Days to start of		5102411	Provide the number of days from the index date
	maintenance			to the date maintenance and/or consolidation
	and/or			therapy started.
	consolidation			
	therapy from			
	index date			
90	Days to last		5102431	Provide the number of days from the index date
	known		5102751	to the last known date of maintenance and/or
	administration			consolidation therapy.
	date of			consolidation anerapy.
	maintenance			
	and/or			
	consolidation			
	therapy from			
	index date			
91	Is the patient still	□ Yes	6379568	Indicate whether the patient is still undergoing
91			0579508	
	receiving			maintenance and/or consolidation therapy.
	treatment?		2400000	
92	Disease status	No evidence of disease	2188290	Provide the disease status following maintenance
		Progressive disease		and/or consolidation therapy.
		□ Stable disease		
		🗖 Unknown		
93	International		5777238	Indicate the patient's INRG stage.
	Neuroblastoma	□ L2		
	Risk Group	Ом		
	classification			
	system stage			
94	INSS stage	Stage 1 Stage 4	2974055	Indicate the patient's International
		□ Stage 2A □ Stage 4S		Neuroblastoma Staging System disease stage.
		□ Stage 2B □ Unknown		
		□ Stage 3		
95	COG risk	Low risk	4616452	Indicate the patient's risk classification according
	classification	Intermediate risk	to the Childr	to the Children's Oncology Group (COG).
		□ High risk		
		🗖 Unknown		
96	INPC grade of	Undifferentiated	4616392	Indicate the grade of neuroblastic differentiation
	neuroblastic	Poorly differentiated		according to the revised International
	differentiation	Differentiating		Neuroblastoma Pathology Classification (INPC).
		🛛 Unknown		
97	Is necrosis	□ Yes	64740	Indicate whether necrosis was present in the
	present?	🗆 No		primary tumor.
		🗖 Unknown		
98	MYCN gene	□ Amplified	4616052	Indicate the amplification status of the MYCN
-	amplification	□ Not amplified		gene.
			I	, v
	status	Not done		



Tissue Source Site (TSS) Name: ______ Completed By: ______

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
99	DNA ploidy	Diploid (DI=1)	4616354	Select the DNA ploidy analysis by flow cytometry
	analysis by flow	Hyperdiploid (DI>1)		test result. Note: If DNA ploidy was hyperdiploid,
	cytometry	Unknown		proceed to Question 100, otherwise, skip to Question 101
100	DNA ploidy		4824055	Specify the numerical result of the DNA ploidy
	analysis by flow			analysis by flow cytometry.
	cytometry result			
	value			
101	INPC mitosis	□ Low	4616412	Indicate the mitosis karyorrhexis index category
	karyorrhexis index	Intermediate		according to the revised International
		🗖 High		Neuroblastoma Pathology Classification (INPC).
		Unknown		
102	Was ALK mutation	□ Yes	3773874	Indicate whether ALK mutation status was
	analysis	D No		assessed. Note: If ALK mutation analysis was not
	performed?			performed, skip to Question 105.
103	Was a mutation in	□ Yes	3774202	Indicate whether a mutation in ALK was
	ALK identified?	🗆 No		identified. Note: If an ALK mutation was not
101		—		identified, skip to Question 105.
104	If ALK mutation	□ F1174C	6060279	If ALK mutation identified, which one? Note: If the ALK mutation is not listed, proceed to Question 104a,
	identified, which	□ F1174L		otherwise, skip to Question 105.
	one?	□ F1174V		otherwise, skip to Question 105.
		□ F1245L		
		□ K1062M		
		□ R1275Q		
		□ T1087I		
		Other (specify)		
104a	Other ALK		6101680	If the ALK mutation identified is not included in
	mutation			the provided list, specify the ALK mutation
				identified.
		Tumor Biospecimen Information (if c	ippiicabie)	
105	Are you			A biospecimen obtained from a single site at a single
	submitting an			timepoint in progression that is portioned for both
	additional			sequencing and model generation counts as 1 single
	additional metastatic/	□ Yes		sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from
	additional metastatic/ recurrent tumor	□ Yes □ No		sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression
	additional metastatic/			sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model
	additional metastatic/ recurrent tumor			sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor
	additional metastatic/ recurrent tumor			sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model
106	additional metastatic/ recurrent tumor		6584266	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i>
106	additional metastatic/ recurrent tumor tissue sample?		6584266	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i>
106	additional metastatic/ recurrent tumor tissue sample? Metastatic/		6584266	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second
106	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue		6584266	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc.
106	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen		6584266	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this
	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal			sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc.
	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal		6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this
	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal			sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID		6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID BPC submitter ID (if available)		6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Submission Form transmitted to the BPC.
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID BPC submitter ID		6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC. Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID BPC submitter ID (if available) Metastatic/ recurrent tumor	□ No	6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample	□ No	6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample preservation	□ No	6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample	□ No	6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample
107	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample preservation	□ No □ Cryopreserved □ FFPE □ Frozen □ OCT	6586035	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample
107 108 109	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample preservation method	□ No □ Cryopreserved □ FFPE □ Frozen □ OCT	6586035 6584919 5432521	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for molecular characterization.
107 108 109	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample preservation method Number of days from index date to	□ No □ Cryopreserved □ FFPE □ Frozen □ OCT	6586035 6584919 5432521	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for molecular characterization.
107 108 109	additional metastatic/ recurrent tumor tissue sample? Metastatic/ recurrent tissue biospecimen ordinal CMDC tissue ID (if available) Metastatic/ recurrent tumor tissue sample preservation method Number of days	□ No □ Cryopreserved □ FFPE □ Frozen □ OCT	6586035 6584919 5432521	sequencing and model generation counts as 1 single tumor specimen. A biospecimen obtained from another site or at a later timepoint in progression that is portioned for both sequencing and model generation counts as a second single tumor specimen. <i>Note: If yes, proceed to Question 106,</i> <i>otherwise, skip to Question 134.</i> Please provide a number to identify which biospecimen this is in the sequence. The first biospecimen should be number "1," the second should be number "2," etc. Please provide the CMDC sample ID for this biospecimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Provide the method used to preserve the metastatic/recurrent tumor tissue sample collected for molecular characterization.



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
111	Method of metastatic/ recurrent cancer sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspiration Incisional biopsy Tumor resection Other method, specify 	6587389	Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue. <i>Note: If the method of procurement is not listed, proceed to Question 111a, otherwise, skip to Question 112.</i>
111a	Other method of cancer sample procurement		6587390	If the procedure performed to obtain the tumor tissue is not included in the provided list, specify the procedure.
112	Number of days from index date to date of metastatic/ recurrent sample procurement		3288495	Provide the number of days from the index date to the date of the procedure that produced the metastatic/recurrent tumor tissue submitted for HCMI.
113	Metastatic/ recurrent site	 Abdominal/non-adrenal Adrenal Ascites Bone Bone marrow Extra-adrenal Lung Lymph node(s) regional Lymph node(s) distant Neck Posterior mediastinum Other (specify) 	6587394	Select the site from which the metastatic/recurrent tissue used to develop the model was derived. Note: If the metastatic/recurrent site is not listed, proceed to Question 113a, otherwise, skip to Question 114.
113a	Other metastatic/ recurrent site		6587395	If not included in the previous list, specify the site from which the metastatic/recurrent tissue used to develop the model was derived.
114	Site of relapse	Local Regional Distant Not applicable	2002506	If the primary tumor relapsed, provide the site of relapse.
115	ICD-10 code		3226287	Provide the ICD-10 code for the metastatic/recurrent tumor used to generate the model submitted to HCMI.
116	ICD-O-3 histology code		3226275	Provide the ICD-O-3 histology code describing the morphology of the metastatic/recurrent tumor used to generate the model submitted to HCMI.
117	Maintenance and/or consolidation therapy administered prior to collection of metastatic/ recurrent tissue		6119066	Provide the name(s) of the maintenance and/or consolidation therapy administered to the patien prior to the collection of the metastatic/recurrent tissue used to develop the model.
118	Days to start of maintenance and/or consolidation therapy from index date		5102411	Provide the number of days from the index date to the date maintenance and/or consolidation therapy started.
119	Days to last known administration date of		5102431	Provide the number of days from the index date to the last known date of maintenance and/or consolidation therapy.



Tissue Source Site (TSS) Name: ______ Completed By: ______

	maintenance and/or consolidation therapy from			
120	index date Is the patient still receiving treatment?	☐ Yes □ No □ Unknown	6379568	Indicate whether the patient is still undergoing maintenance and/or consolidation therapy.
121	Disease status	 No evidence of disease Progressive disease Stable disease Unknown 	2188290	Provide the disease status following maintenance and/or consolidation therapy.
122	International Neuroblastoma Risk Group classification system stage	□ L1 □ L2 □ M □ MS	5777238	Indicate the patient's INRG stage.
123	INSS stage	Stage 1 Stage 4 Stage 2A Stage 4S Stage 2B Unknown Stage 3 Stage 3	2974055	Indicate the patient's International Neuroblastoma Staging System disease stage.
124	COG risk classification	 Low risk Intermediate risk High risk Unknown 	4616452	Indicate the patient's risk classification according to the Children's Oncology Group (COG).
125	INPC grade of neuroblastic differentiation	 Undifferentiated Poorly differentiated Differentiating Unknown 	4616392	Indicate the grade of neuroblastic differentiation according to the revised International Neuroblastoma Pathology Classification (INPC).
126	ls necrosis present?	Yes No Unknown	64740	Indicate whether necrosis was present in the primary tumor.
127	MYCN gene amplification status	 Amplified Not amplified Not done Unknown 	4616052	Indicate the amplification status of the MYCN gene.
128	DNA ploidy analysis by flow cytometry	Diploid (DI=1) Hyperdiploid (DI>1) Unknown	4616354	Select the DNA ploidy analysis by flow cytometry test result. <i>Note: If DNA ploidy was hyperdiploid, proceed to Question 129, otherwise, skip to Question 130.</i>
129	DNA ploidy analysis by flow cytometry result value		4824055	Specify the numerical result of the DNA ploidy analysis by flow cytometry.
130	INPC mitosis karyorrhexis index	Low Intermediate High Unknown	4616412	Indicate the mitosis karyorrhexis index category according to the revised International Neuroblastoma Pathology Classification (INPC).
131	Was ALK mutation analysis performed?	Yes No Unknown	3773874	Indicate whether ALK mutation status was assessed. Note: If ALK mutation analysis was not performed, skip to Question 134.
132	Was a mutation in ALK identified?	□ Yes □ No	3774202	Indicate whether a mutation in ALK was identified. Note: If an ALK mutation was not identified, skip to Question 134.
133	If ALK mutation identified, which one?	□ F1174C □ K1062M □ F1174L □ R1275Q □ F1174V □ T1087I □ F1245L □ Other (specify)	6060279	If ALK mutation identified, which one? <i>Note: If the</i> <i>ALK mutation is not listed, proceed to Question 133a,</i> <i>otherwise, skip to Question 134.</i>



Tissue Source Site (TSS) Name: _____ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
133a	Other ALK		6101680	If the ALK mutation identified is not included in
	mutation			the provided list, specify the ALK mutation
				identified.
//////////////////////////////////////	Recurrent Tumor Mo	odel Information		1
134	METASTATIC/		6594587	Please provide a number to identify
	RECURRENT			which biospecimen this is in the sequence. Note:
	model			The first biospecimen should be number "1," the
	biospecimen			second should be number "2," etc.
	ordinal			
135	CMDC model ID		6586036	Please provide the CMDC model ID
				for this sample as it will appear
				on tubes and the Sample Submission
				Form transmitted to the BPC.
136	BPC submitter ID		6584919	Please provide the BPC-generated ID
	(if available)			for this sample as it will appear on the
				Sample Submission Form transmitted
				to the BPC.
407		+		
137	Model's		6586035	Enter the CMDC Sample ID of the
	METASTATIC/			METASTATIC/RECURRENT tissue from which this
	RECURRENT			model is derived.
	tumor tissue			
120	CMDC sample ID		6504266	Futer the bicenceimen ending!
138	Model's		6584266	Enter the biospecimen ordinal
	METASTATIC/			of the METASTATIC/RECURRENT tissue from
	RECURRENT			which this model is derived.
	tumor tissue			
	biospecimen ordinal			
Additional		L t Biospecimen Tumor Model Informa	tion (if annlicable)	
139	METASTATIC/		6594587	Please provide a number to identify
133	RECURRENT		0554587	which biospecimen this is in the sequence. <i>Note:</i>
	model			The first biospecimen should be number "1," the
	biospecimen			second should be number "2," etc.
	ordinal			
140	CMDC model ID		6586036	Please provide the CMDC model ID for this
140	chibe model ib		0500050	sample as it will appear on tubes and the Sample
				Submission Form transmitted to the BPC.
1/1	BBC submitter ID		6584010	
141	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
141	BPC submitter ID (if available)		6584919	Please provide the BPC-generated ID for this sample as it will appear on the Sample
	(if available)			Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
141	(if available) Model's		6584919	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the
	(if available) Model's METASTATIC/			Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this
	(if available) Model's METASTATIC/ RECURRENT			Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the
	(if available) Model's METASTATIC/ RECURRENT tumor tissue			Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived.
	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's			Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen ordinal		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this
142 143 Dther Biosp	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen ordinal eccimen Information		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived.
142	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen ordinal eccimen Information Are you		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived.
142 143 Dther Biosp	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen ordinal eccimen Information Are you submitting an		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived.
142 143 Dther Biosp	(if available) Model's METASTATIC/ RECURRENT tumor tissue CMDC sample ID Model's METASTATIC/ RECURRENT tumor tissue biospecimen ordinal eccimen Information Are you		6586035	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC. Enter the CMDC Sample ID of the METASTATIC/RECURRENT tissue from which this model is derived. Enter the biospecimen ordinal of the METASTATIC/RECURRENT tissue from which this model is derived.



Tissue Source Site (TSS) Name: ______ Completed By: _____ Enrollment: Neuroblastoma

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
145	OTHER tissue		6584267	Please provide a number to identify
	biospecimen			which biospecimen this is in the sequence. Note:
	ordinal			The first biospecimen should be number "1," the
				second should be number "2," etc.
146	CMDC sample ID		6586035	Please provide the CMDC sample ID
				for this specimen as it will appear on tubes and
				the Sample Submission Form transmitted to the
				BPC.
147	BPC submitter ID		6584919	Please provide the BPC-generated ID for this
	(if available)			sample as it will appear on the Sample
	(Submission Form transmitted
				to the BPC.
148	OTHER tissue	Cryopreserved	5432521	Provide the method used to preserve the OTHER
140		, ,	5452521	
	sample			tissue sample collected for
	preservation	Frozen		molecular characterization.
	method	🗆 ОСТ		
		Snap frozen		
149	Method of OTHER	Core needle biopsy	6587389	Indicate the procedure performed to obtain the
	tissue sample	Excisional biopsy		metastatic/recurrent tumor tissue. Note: If the
	procurement	□ Fine needle aspiration		method of procurement is not listed, proceed to
	procurement	Incisional biopsy		Question 149a, otherwise, skip to Question 150.
		Tumor resection		
		 Other method, specify 		
149a	Specify method of		6587399	Specify the procedure performed to obtain the
1490	OTHER tissue		0307399	OTHER tissue.
				OTHER USSUE.
	sample .			
	procurement			
150	Number of days		3288495	Provide the number of days from the index date
	from index date to			to the date of the procedure that produced the
	date of			OTHER tissue submitted for HCMI.
	OTHER sample			
	procurement			
151	Tissue type		64784	Indicate the OTHER tissue type.
		Pre-malignant		Note: If the OTHER tissue type is not listed, proceed to
		Other (specify)		Question 151a, otherwise, skip to Question 152.
151a	Specify tissue type		64785	Specify the OTHER tissue type if not in the
				provided list.
152	Anatomic site of	Abdominal/non-adrenal	6696813	Select the site from which the OTHER tissue use
	OTHER tissue	□ Adrenal		to develop the model was derived. <i>Note: If the</i>
		□ Ascites		OTHER tissue site is not listed, proceed to Question
		□ Bone		152a, otherwise, skip to Question 153.
		□ Bone marrow		
		Extra-adrenal		
		Lymph node(s) regional		
		Lymph node(s) distant		
		Neck		
		Posterior mediastinum		
		Other (specify)		
152a	Specify anatomic		6584916	Specify the site of OTHER tissue, if not in the
	site of OTHER			previous list.
	tissue			
153	ICD-10 code		3226287	Provide the ICD-10 code for the OTHER tissue
				used to generate the model submitted to HCMI.
154	ICD-O-3 histology		3226275	Provide the ICD-O-3 histology code
154			5220275	
	code			describing the morphology of the OTHER tissue



Tissue Source Site (TSS) Name: _____ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
Additional	OTHER biospecimen Ir	formation (if applicable)		
155	Are you submitting an additional OTHER tissue sample?	□ Yes □ No		Indicate whether an additional OTHER tissue sample (pre-malignant, non-malignant, or dysplastic tissue, etc.) is being submitted for HCMI for this case. <i>Note: If yes, proceed to Question</i> <i>156, otherwise, skip to Question 166.</i>
156	OTHER tissue biospecimen ordinal		6584267	Please provide a number to identify which biospecimen this is in the sequence. <i>Note:</i> <i>The first biospecimen should be number "1," the</i> <i>second should be number "2," etc.</i>
157	CMDC sample ID		6586035	Please provide the CMDC sample ID for this specimen as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
158	BPC submitter ID (if available)	·	6584919	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
159	OTHER tissue sample preservation method	Cryopreserved FFPE Frozen OCT Snap frozen	5432521	Provide the method used to preserve the OTHER tissue sample collected for molecular characterization.
160	Method of OTHER tissue sample procurement	 Core needle biopsy Excisional biopsy Fine needle aspiration Incisional biopsy Tumor resection Other method, specify 	6587389	Indicate the procedure performed to obtain the metastatic/recurrent tumor tissue. <i>Note: If the</i> <i>method of procurement is not listed, proceed to</i> <i>Question 160a, otherwise, skip to Question 161.</i>
160a	Specify method of OTHER tissue sample procurement		6587399	Specify the procedure performed to obtain the OTHER tissue.
161	Number of days from index date to date of OTHER sample procurement		3288495	Provide the number of days from the index date to the date of the procedure that produced the OTHER tissue submitted for HCMI.
162	Tissue type	Pre-malignantOther (specify)	64784	Indicate the OTHER tissue type. Note: If the OTHER tissue type is not listed, proceed to Question 162a, otherwise, skip to Question 163.
162a	Specify tissue type		64785	Specify the OTHER tissue type if not in the provided list.
163	Anatomic site of OTHER tissue	 Abdominal/non-adrenal Adrenal Ascites Bone Bone marrow Extra-adrenal Lung Lymph node(s) regional Lymph node(s) distant Neck Posterior mediastinum Other (specify) 	6696813	Select the site from which the OTHER tissue used to develop the model was derived. <i>Note: If the</i> <i>OTHER tissue site is not listed, proceed to Question</i> <i>163a, otherwise, skip to Question 164.</i>
163a	Specify anatomic site of OTHER tissue		6584916	Specify the site of OTHER tissue, if not in the previous list.



Tissue Source Site (TSS) Name: ______ Completed By: _____

Question	Question Text	Data Entry Options	CDE ID	Instruction Text
164	ICD-10 code		3226287	Provide the ICD-10 code for the OTHER tissue used to generate the model submitted to HCMI.
165	ICD-O-3 histology code		3226275	Provide the ICD-O-3 histology code describing the morphology of the OTHER tissue used to generate the model submitted to HCMI.
Other Tissu	e Model Information			
166	OTHER tissue model biospecimen ordinal		6594590	Please provide a number to identify which biospecimen this is in the sequence. <i>Note:</i> <i>The first biospecimen should be number "1," the</i> <i>second should be number "2," etc.</i>
167	CMDC model ID		6586036	Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
168	BPC submitter ID (if available)		6584919	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
169	Model's OTHER tissue CMDC sample ID		6586035	Enter the CMDC Sample ID of the OTHER tissue from which this model is derived.
170	Model's OTHER tissue biospecimen ordinal		6584267	Enter the biospecimen ordinal of the OTHER tissue from which this model is derived.
Additional	Other Tissue Model In	formation (if applicable)		
171	OTHER tissue model biospecimen ordinal		6594590	Please provide a number to identify which biospecimen this is in the sequence. <i>Note:</i> <i>The first biospecimen should be number "1," the</i> <i>second should be number "2," etc.</i>
172	CMDC model ID		6586036	Please provide the CMDC model ID for this sample as it will appear on tubes and the Sample Submission Form transmitted to the BPC.
173	BPC submitter ID (if available)		6584919	Please provide the BPC-generated ID for this sample as it will appear on the Sample Submission Form transmitted to the BPC.
174	Model's OTHER tissue CMDC sample ID		6586035	Enter the CMDC Sample ID of the OTHER tissue from which this model is derived.